Background: HIV-1 transmitted drug resistance (TDR) could reverse the gains of
Introduction
Concern that a rapid massive scale-up of antiretroviral therapy (ART) would lead to the widespread emergence and transmission of drug resistant virus 1, 2 was expressed early in the development of ART access programs in Africa. These were based largely on the challenges associated with early treatments (high pill burden, frequent dosing, toxicity) and financial constraints that would cause drug "stock- TDR levels vary widely, depending on factors such as the population studied, availability and access to ART, duration of the treatment programs, quality of medical care, risk-taking behaviours, mode of transmission and viral subtype 9, 10 . In developed countries, the use of mono-and dual-therapy in the pre-HAART era (1980's and early 1990's) resulted in the rapid emergence of TDR with peak levels as high as 27% [11] [12] [13] [14] [15] [16] [17] in some population groups. However, recent evidence suggests that TDR is decreasing with the current levels ranging between 5 to 15% in Europe (2007) and 10 to 18% in the US 18 . Since transmitted resistance can seriously limit future therapeutic options, North American and European treatment guidelines This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
recommend resistance testing for all treatment-naïve patients prior to the initiation of highly active combination ART (HAART). This provides an opportunity to avoid ineffective drug combinations and allows for individualized optimization of first-line HAART.
In This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
date, most WHO "threshold" surveys have been conducted in the antenatal setting.
Whether the results can be extrapolated to the general population remains to be determined. Population-based estimates of TDR are rare but can be derived from surveillance, prevention and vaccine studies including the identification of individuals with laboratory evidence of recent infection.
The current population-based study is nested within a large 7-year HIV-1 surveillance study conducted in the Hlabisa sub-district of rural KwaZulu-Natal (KZN) 
Methods and Materials

Study participants
The Africa Centre hosts a large demographic and health surveillance in a 
Analysis and interpretation of sequence results
Protease and reverse transcriptase nucleotide sequences were assembled using Geneious Pro genetic analyzer 28 . Quality assessment and HIV subtyping of these sequences were performed using the HIV-1 Quality Analysis Tool and REGA HIV-1 Subtyping Tool v 2.0 respectively 29, 30 . To aid in quality assurance, neighbor joining phylogenetic trees were created in Geneious using ClustalW for sequence This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
Of the 91 samples selected for drug resistance testing, 72 (79%) were successfully genotyped. As would be expected, the majority (71/72, 99%) of recent seroconverters were infected with HIV-1 C subtype, the predominant subtype in KZN:
the remaining seroconverter was infected with subtype A. There was no evidence of transmitted drug resistance in the samples of the 72 seroconverters tested.
Changes in prevalence of TDR mutations over the past 20 years
The PUBMED search identified 32 HIV-1 drug resistance studies. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
clinically relevant resistance) and methods used to assess resistance (phenotypic, genotypic assays of varying sensitivity ranging from population-based sequencing, allele specific priming, deep sequencing) 9 . These biases make it difficult to make firm epidemiological generalizations based on the prevalence and trends of TDR in individual demographic and population groups.
Nevertheless, despite differences between the Africa Centre and previous TDR studies conducted in Gauteng, the Free State, the Western Cape and KZN, we were able to create a temporal profile of primary resistance in South Africa over the This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. 
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